Todd Harris - 24 Mar 2023 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Signature
/s/ Ali D. Fawaz, Attorney-in-Fact
Issuer symbol
TYRA
Transactions as of
24 Mar 2023
Transactions value $
-$81,290
Form type
4
Filing time
28 Mar 2023, 19:09:04 UTC
Previous filing
23 Mar 2023
Next filing
31 Mar 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Options Exercise $382 +170 +0.01% $2.25* 1,701,446 24 Mar 2023 Direct
transaction TYRA Common Stock Sale -$2,720 -170 -0.01% $16 1,701,276 24 Mar 2023 Direct F1
transaction TYRA Common Stock Options Exercise $6,666 +2,963 +0.17% $2.25* 1,704,239 27 Mar 2023 Direct
transaction TYRA Common Stock Sale -$47,408 -2,963 -0.17% $16 1,701,276 27 Mar 2023 Direct F1
transaction TYRA Common Stock Options Exercise $6,252 +2,779 +0.16% $2.25* 1,704,055 28 Mar 2023 Direct
transaction TYRA Common Stock Sale -$44,464 -2,779 -0.16% $16 1,701,276 28 Mar 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -170 -0.04% $0 409,606 24 Mar 2023 Common Stock 170 $2.25 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -2,963 -0.72% $0 406,643 27 Mar 2023 Common Stock 2,963 $2.25 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -2,779 -0.68% $0 403,864 28 Mar 2023 Common Stock 2,779 $2.25 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022.
F2 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.